Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.

Last week, stocks pulled back from record highs as oil, yields, and rate fears returned to the forefront. The S&P 500 (SPX) ended at 7,408.50, down...

The Week That Was, The Week Ahead: Macro and Markets, May 17

Viatris ( ($VTRS) ) has provided an update. On May 15, 2026, Viatris Inc. held its 2026 annual meeting of shareholders, where investors voted on bo...

Viatris Shareholders Approve Directors, Pay and Auditor

In a report released today, Les Sulewski from Truist Financial reiterated a Buy rating on Viatris, with a price target of $20.00. According to TipR...

Market Cap	$12.77B	P/E Ratio	6.58
52W High	$17.53	52W Low	$8.19
Div Yield	48.0%	Payout Ratio	-40.6%
EPS Growth 3Y	-100.0%	52W Position	86.4%
Overall Score	61	Value Score	80
Quality Score	50	Technical Score	54

EPS Current Est	$2.47	EPS Next Est	$2.7
EPS Growth Est	+9.3%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTRS	$16.26	-2.34%	11.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTRS	$16.26	-2.3%	11.33M
3
4
5
6

VTRS

VTRS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Viatris Inc. Data in Excel

Get Viatris Inc. Data in Excel